Antidepressant Drugs Market 2027 By Depressive Disorder, Product and Geography | The Insight Partners

Antidepressant Drugs Market to 2027 - Global Analysis and Forecasts by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others); Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Others)and Geography

Report Code: TIPRE00004581 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
The depression is the mood disorder that give a continue feeling of sadness and loss of interest. There are many factors which leads to the depression such as inherited traits, hormones, stress, brain chemistry which can cause the depression. The antidepressants help to maintain the balance between the brain chemistry and hormonal changes which is used for treatment of depression. Depression require long time of treatment it can be treated by specific treatment or psychotherapy.

MARKET DYNAMICS
The Antidepressant Drugs Market is anticipated to grow in the forecast period owing to driving factors such as increasing geriatric population, increasing prevalence of depression, and development of new drug with minor side effect is driving the growth of market. However the concerns for efficacy and safety of drug and preference to the non-pharmacological therapy harms the growth of market.

MARKET SCOPE
The "Global Antidepressant Drugs Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of antidepressant drugs market with detailed market segmentation by depressive disorder, product and geography. The global antidepressant drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading antidepressant drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global antidepressant drugs market is segmented on the basis of depressive disorder and product. Based on depressive disorder, the market is segmented as major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, others. On the basis of product, the global antidepressant drugs market is segmented into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global antidepressant drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The antidepressant drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting antidepressant drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the antidepressant drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the antidepressant drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from antidepressant drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Antidepressant Drugs in the global market. Below mentioned is the list of few companies engaged in the antidepressant drugs market.

The report also includes the profiles of key antidepressant drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Alkermes Plc.
  • Allergan Plc.
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • H. Lundbeck
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antidepressant Drugs - By Depressive Disorder
1.3.2 Antidepressant Drugs - By Product
1.3.3 Antidepressant Drugs - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. ANTIDEPRESSANT DRUGS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIDEPRESSANT DRUGS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTIDEPRESSANT DRUGS - GLOBAL MARKET ANALYSIS
6.1. ANTIDEPRESSANT DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTIDEPRESSANT DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIDEPRESSANT DRUGS - REVENUE AND FORECASTS TO 2027 - DEPRESSIVE DISORDER
7.1. OVERVIEW
7.2. DEPRESSIVE DISORDER MARKET FORECASTS AND ANALYSIS
7.3. MAJOR DEPRESSIVE DISORDER
7.3.1. Overview
7.3.2. Major Depressive Disorder Market Forecast and Analysis
7.4. OBSESSIVE-COMPULSIVE DISORDER
7.4.1. Overview
7.4.2. Obsessive-Compulsive Disorder Market Forecast and Analysis
7.5. GENERALIZED ANXIETY DISORDER
7.5.1. Overview
7.5.2. Generalized Anxiety Disorder Market Forecast and Analysis
7.6. PANIC DISORDER
7.6.1. Overview
7.6.2. Panic Disorder Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ANTIDEPRESSANT DRUGS - REVENUE AND FORECASTS TO 2027 - PRODUCT
8.1. OVERVIEW
8.2. PRODUCT MARKET FORECASTS AND ANALYSIS
8.3. TRICYCLIC ANTIDEPRESSANTS
8.3.1. Overview
8.3.2. Tricyclic Antidepressants Market Forecast and Analysis
8.4. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
8.4.1. Overview
8.4.2. Selective Serotonin Reuptake Inhibitors Market Forecast and Analysis
8.5. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
8.5.1. Overview
8.5.2. Serotonin-Norepinephrine Reuptake Inhibitors Market Forecast and Analysis
8.6. MONOAMINE OXIDASE INHIBITORS
8.6.1. Overview
8.6.2. Monoamine Oxidase Inhibitors Market Forecast and Analysis
8.7. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS
8.7.1. Overview
8.7.2. Serotonin Antagonist and Reuptake Inhibitors Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. ANTIDEPRESSANT DRUGS REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Antidepressant Drugs Overview
9.1.2 North America Antidepressant Drugs Forecasts and Analysis
9.1.3 North America Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.1.4 North America Antidepressant Drugs Forecasts and Analysis - By Product
9.1.5 North America Antidepressant Drugs Forecasts and Analysis - By Countries
9.1.5.1 United States Antidepressant Drugs
9.1.5.1.1 United States Antidepressant Drugs by Depressive Disorder
9.1.5.1.2 United States Antidepressant Drugs by Product
9.1.5.2 Canada Antidepressant Drugs
9.1.5.2.1 Canada Antidepressant Drugs by Depressive Disorder
9.1.5.2.2 Canada Antidepressant Drugs by Product
9.1.5.3 Mexico Antidepressant Drugs
9.1.5.3.1 Mexico Antidepressant Drugs by Depressive Disorder
9.1.5.3.2 Mexico Antidepressant Drugs by Product
9.2. EUROPE
9.2.1 Europe Antidepressant Drugs Overview
9.2.2 Europe Antidepressant Drugs Forecasts and Analysis
9.2.3 Europe Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.2.4 Europe Antidepressant Drugs Forecasts and Analysis - By Product
9.2.5 Europe Antidepressant Drugs Forecasts and Analysis - By Countries
9.2.5.1 Germany Antidepressant Drugs
9.2.5.1.1 Germany Antidepressant Drugs by Depressive Disorder
9.2.5.1.2 Germany Antidepressant Drugs by Product
9.2.5.2 France Antidepressant Drugs
9.2.5.2.1 France Antidepressant Drugs by Depressive Disorder
9.2.5.2.2 France Antidepressant Drugs by Product
9.2.5.3 Italy Antidepressant Drugs
9.2.5.3.1 Italy Antidepressant Drugs by Depressive Disorder
9.2.5.3.2 Italy Antidepressant Drugs by Product
9.2.5.4 Spain Antidepressant Drugs
9.2.5.4.1 Spain Antidepressant Drugs by Depressive Disorder
9.2.5.4.2 Spain Antidepressant Drugs by Product
9.2.5.5 United Kingdom Antidepressant Drugs
9.2.5.5.1 United Kingdom Antidepressant Drugs by Depressive Disorder
9.2.5.5.2 United Kingdom Antidepressant Drugs by Product
9.2.5.6 Rest of Europe Antidepressant Drugs
9.2.5.6.1 Rest of Europe Antidepressant Drugs by Depressive Disorder
9.2.5.6.2 Rest of Europe Antidepressant Drugs by Product
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Antidepressant Drugs Overview
9.3.2 Asia-Pacific Antidepressant Drugs Forecasts and Analysis
9.3.3 Asia-Pacific Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.3.4 Asia-Pacific Antidepressant Drugs Forecasts and Analysis - By Product
9.3.5 Asia-Pacific Antidepressant Drugs Forecasts and Analysis - By Countries
9.3.5.1 Australia Antidepressant Drugs
9.3.5.1.1 Australia Antidepressant Drugs by Depressive Disorder
9.3.5.1.2 Australia Antidepressant Drugs by Product
9.3.5.2 China Antidepressant Drugs
9.3.5.2.1 China Antidepressant Drugs by Depressive Disorder
9.3.5.2.2 China Antidepressant Drugs by Product
9.3.5.3 India Antidepressant Drugs
9.3.5.3.1 India Antidepressant Drugs by Depressive Disorder
9.3.5.3.2 India Antidepressant Drugs by Product
9.3.5.4 Japan Antidepressant Drugs
9.3.5.4.1 Japan Antidepressant Drugs by Depressive Disorder
9.3.5.4.2 Japan Antidepressant Drugs by Product
9.3.5.5 South Korea Antidepressant Drugs
9.3.5.5.1 South Korea Antidepressant Drugs by Depressive Disorder
9.3.5.5.2 South Korea Antidepressant Drugs by Product
9.3.5.6 Rest of Asia-Pacific Antidepressant Drugs
9.3.5.6.1 Rest of Asia-Pacific Antidepressant Drugs by Depressive Disorder
9.3.5.6.2 Rest of Asia-Pacific Antidepressant Drugs by Product
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Antidepressant Drugs Overview
9.4.2 Middle East and Africa Antidepressant Drugs Forecasts and Analysis
9.4.3 Middle East and Africa Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.4.4 Middle East and Africa Antidepressant Drugs Forecasts and Analysis - By Product
9.4.5 Middle East and Africa Antidepressant Drugs Forecasts and Analysis - By Countries
9.4.5.1 South Africa Antidepressant Drugs
9.4.5.1.1 South Africa Antidepressant Drugs by Depressive Disorder
9.4.5.1.2 South Africa Antidepressant Drugs by Product
9.4.5.2 Saudi Arabia Antidepressant Drugs
9.4.5.2.1 Saudi Arabia Antidepressant Drugs by Depressive Disorder
9.4.5.2.2 Saudi Arabia Antidepressant Drugs by Product
9.4.5.3 U.A.E Antidepressant Drugs
9.4.5.3.1 U.A.E Antidepressant Drugs by Depressive Disorder
9.4.5.3.2 U.A.E Antidepressant Drugs by Product
9.4.5.4 Rest of Middle East and Africa Antidepressant Drugs
9.4.5.4.1 Rest of Middle East and Africa Antidepressant Drugs by Depressive Disorder
9.4.5.4.2 Rest of Middle East and Africa Antidepressant Drugs by Product
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Antidepressant Drugs Overview
9.5.2 South and Central America Antidepressant Drugs Forecasts and Analysis
9.5.3 South and Central America Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.5.4 South and Central America Antidepressant Drugs Forecasts and Analysis - By Product
9.5.5 South and Central America Antidepressant Drugs Forecasts and Analysis - By Countries
9.5.5.1 Brazil Antidepressant Drugs
9.5.5.1.1 Brazil Antidepressant Drugs by Depressive Disorder
9.5.5.1.2 Brazil Antidepressant Drugs by Product
9.5.5.2 Argentina Antidepressant Drugs
9.5.5.2.1 Argentina Antidepressant Drugs by Depressive Disorder
9.5.5.2.2 Argentina Antidepressant Drugs by Product
9.5.5.3 Rest of South and Central America Antidepressant Drugs
9.5.5.3.1 Rest of South and Central America Antidepressant Drugs by Depressive Disorder
9.5.5.3.2 Rest of South and Central America Antidepressant Drugs by Product
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTIDEPRESSANT DRUGS, KEY COMPANY PROFILES
11.1. ALKERMES PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ALLERGAN PLC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BRISTOL MYERS SQUIBB CO.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ELI LILLY AND CO.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. H. LUNDBECK
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK & CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TAKEDA PHARMACEUTICAL CO. LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments


12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Alkermes Plc.
2. Allergan Plc.
3. Bristol Myers Squibb Co.
4. Eli Lilly and Co.
5. GlaxoSmithKline Plc.
6. H. Lundbeck
7. Merck & Co., Inc.
8. Pfizer Inc.
9. Teva Pharmaceutical Industries Ltd.
10. Takeda Pharmaceutical Co. Ltd.